Point-of-care testing identifies ARDS inflammatory subphenotypes in real time, offering insights into patient prognosis and mortality risks.
For patients on long-term oral anticoagulation therapy, use of point-of-care devices is associated with lower rates of death and major thromboembolic events compared with laboratory determinations of ...